1. Introduction {#s0005}
===============

Inflammatory bowel diseases (IBDs) including Crohn\'s disease and ulcerative colitis ([@bb0010]; [@bb0015]) are typically characterized by chronic, progressive, and relapsing inflammation of the intestine. Although the exact pathogenesis of IBD is unknown, it is considered to generally result from multiple immune, genetic, and environmental factors, with only suboptimal medical and surgical therapies being available ([@bb0050]). Previous studies have suggested that although the pathogenesis of ulcerative colitis and Crohn\'s disease is similar, important differences do exist ([@bb0230]). Ulcerative colitis is characterized by relapsing and remitting mucosal inflammation, often initiating in the rectum and extending to proximal segments of the colon ([@bb0230]). However, Crohn\'s disease constitutes a chronic, relapsing, systemic inflammatory disease that mainly affects the gastrointestinal tract, along with extra-intestinal manifestations and associated immune disorders ([@bb0010]).

GPR109A constitutes a G~i~ protein-coupled receptor that is activated by nicotinic acid ([@bb0205]; [@bb0225]; [@bb0240]), butyrate ([@bb0220]), and beta-hydroxybutyric acid ([@bb0215]). Previous studies have shown that the activation of GPR109A suppresses mammary tumorigenesis by inducing apoptosis in breast cancer cells ([@bb0040]). GPR109A is also linked to a pro-apoptotic pathway in neutrophils, suggesting that nicotinic acid may mediate anti-inflammatory effects in addition to its inhibitory function on adipocyte lipolysis ([@bb0105]). Moreover, as the ligand of GPR109A, niacin acid has the ability to reduce inflammation in atherosclerosis ([@bb0120]), obesity ([@bb0235]), sepsis ([@bb0110]), diabetic retinopathy ([@bb0065]), renal disease ([@bb0030]), and Parkinson\'s disease ([@bb0055]; [@bb0060]). Together, these findings indicated that GPR109A has the ability to inhibit inflammation in various diseases. In particular, studies have reported that the GPR109A receptor mediates the protective effects of dietary fiber on gut homeostasis through regulation of the inflammasome in dextran sulfate sodium (DSS)-induced mice ([@bb0135]) and suppresses colonic inflammation and tumorigenesis in mice ([@bb0195]; [@bb0220]). However, the mechanism underlying GPR109A mediation of the process by which butyric acid inhibits inflammation and maintains epithelial barrier integrity in inflammatory bowel disease has not yet been elucidated.

Butyrate, which is produced by bowel microbial fermentation of dietary carbohydrates, fibers, proteins, and peptides ([@bb0075]; [@bb0115]; [@bb0130]), serves as the energy source of small intestinal epithelial cells ([@bb0025]), thus stimulating their growth ([@bb0075]). In this study, mice (*in vivo*) and cells (*in vitro*) were pre-treated with sodium butyrate (SB), a ligand of GPR109A, to explore the anti-inflammatory effects and functional mechanism of the GPR109A receptor.

2. Materials and Methods {#s0010}
========================

2.1. Animals and Models {#s0015}
-----------------------

For all experiments, we utilized 6--8-week-old male *GPR109a*^*−/−*^ and wild-type (*WT*) C57BL/6 mice. The *GPR109a*^*−/−*^ is whole body KO which was a generous gift form Dr. Martin Sager (Zentrale Einrichtung für Tierforschung und Tierschutzaufgaben der Heinrich-Heine Universität Düsseldorf, Germany). The *WT* mice were provided by the Centre of Experimental Animals of the Baiqiuen Medical College of Jilin University (Changchun, China). Mice were housed at 22--23 °C, with a 12 h/12 h light/dark cycle, and *ad libitum* access to food and water. The experiments were approved by the Jilin University Institutional Animal Care and Use Committee. For the 2,4,6-trinitrobenzene sulfonic acid (TNBS) model, colitis was induced by intracolonic administration of TNBS, as previously described ([@bb0165]). Briefly, mice were lightly anesthetized *via* inhalation of diethyl ether. Then, 3.5 mg of TNBS in the 100 μL of 30% ethanol solution was administered into the colon through a catheter inserted approximately 3 cm into the anus.

2.2. Experimental Groups {#s0020}
------------------------

Mice were randomly assigned to six groups, each containing 14 mice. Sham-*WT* and Sham-*GPR109a*^*−/−*^ were used as the normal control groups, TNBS-*WT*, and TNBS-*GPR109a*^*−/−*^ comprised the TNBS treatment groups, and SB-TNBS-*WT* and SB-TNBS-*GPR109a*^*−/−*^ included mice that were first administered SB *via* their drinking water for 6 weeks before being treated with TNBS.

2.3. Disease Activity Index {#s0025}
---------------------------

During the experiment, body weight, stool character and fecal occult blood were recorded. The disease activity index (DAI) was calculated based on the scoring system as shown in [Table 1](#t0005){ref-type="table"} as previously described ([@bb0145]).Unlabelled TableScoreWeight loss (%)Stool characterFecal occult blood00Normal formedNegative11--5%25--10%Loose stoolPositive310--20%4\>20%DiarrheaGross bleedingTable 1Primers used for qRT-PCR.Table 1GenePrimer sequence*Tnfa*F:5′-GCAACTGCTGCACGAAATC-3′R:5′-CTGCTTGTCCTCTGCCCAC-3′*Il6*F:5′-CCAGAAACCGCTATGAAGTTCC-3′R:5′-GTTGGGAGTGGTATCCTCTGTGA-3′*Cldn1 (mou)*F:5′-AGGTCTGGCGACATTAGTGG-3′R:5′-CGTGGTGTTGGGTAAGAGGT-3′*Ocln (mou)*F:5′-ACACTTGCTTGGGACAGAGG-3′R:5′-AAGGAAGCGATGAAGCAGAA-3′*Zo1 (mou)*F: 5′-GACCTTGATTTGCATGACGA-3′R: 5′-AGGACCGTGTAATGGCAGAC-3'*CLDN1 (hum)*F: 5′-CCCTTTGATCCCTACCAACA-3′R: 5′-CAGGACAGGAACAGGAGAGC-3′*OCLN (hum)*F: 5′-ATGGCTGCCTTTTGTTTCAT-3′R: 5′-ATGCCCAGGATAGCACTCAC-3′*ZO1 (hum)*F: 5′-CTCCTGGATTTGGATTTGGA-3′R: 5′-CTGTCCTTCAGCTGGTCCTC-3′*β-actin (mou)*F: 5′-GTCAGGTCATCACTATCGGCAAT-3′R: 5′AGAGGTCTTTACGGATGTCAACGT-3′*GAPDH (hum)*F: 5′-CTCCTGGATTTGGATTTGGA-3′R: 5′-CTGTCCTTCAGCTGGTCCTC-3'

2.4. Hematoxylin and Eosin (H&E)-Staining and Immunofluorescence {#s0030}
----------------------------------------------------------------

Colonic segments (approximately 2--3 cm long) were excised, washed in phosphate buffered saline (PBS), fixed in 4% formaldehyde, embedded in paraffin, and sectioned (5 μm). One set of paraffin sections was stained with H&E, and the total damage score was determined based on the goblet cell depletion (presence = 1, absence = 0), crypt abscesses (presence = 1, absence = 0), mucosal architecture destruction (normal = 1, moderate = 2, extensive = 3), muscle thickening (normal = 1, moderate = 2, extensive = 3), and cellular infiltration (normal = 1, moderate = 2, transmural = 3). The remaining sections were used for immunofluorescence; detailed procedures can be found in [@bb0180]. Briefly, antigens were unmasked by boiling under pressure in sodium citrate buffer. Sections were cooled to room temperature (approximately 25 °C) naturally, then washed three times (5 min each time) with PBS. Sections were then incubated with a blocking buffer (5% donkey serum and 0.1% Triton X-100 in PBS) against the species of the secondary antibody for 60 min. Primary antibodies were incubated at 4 °C overnight, and then washed three times with PBS. Secondary antibodies were diluted to 1:1000, incubated for 1 h at room temperature, and then washed three times in PBS. Nuclei were counterstained using DAPI.

2.5. *In vivo* Intestinal Permeability Assay {#s0035}
--------------------------------------------

Intestinal permeability was evaluated using fluorescein isothiocyanate (FITC)-dextran with an average molecular weight of 3000--5000 (Sigma-Aldrich, St. Louis, MO), as previously described ([@bb0095]). Briefly, 2 days after TNBS treatment, mice were starved for 4 h and then gavaged with FITC-dextran (0.6 mg/g body weight at a concentration of 125 mg/mL). After 4 h, blood was collected from the eyes of the mice and centrifuged at 12,000*g* for 3 min. The FITC-dextran content in serum was determined using a microplate reader with excitation and emission wavelengths of 490 and 525 nm, respectively. Each sample was measured in triplicate.

2.6. Cell Culture {#s0040}
-----------------

Caco-2 cells and RAW246.7 macrophages, purchased from BeNa Culture Collection (Beijing, China), were cultured in Dulbecco\'s modified Eagle\'s medium (Gibco, Grand Island, NY) containing 10% fetal bovine serum (Clark, Australia) and were maintained at 37 °C in a humidified chamber of 5% CO~2~.

The mice were intraperitoneally injected with 4 mL of 3% thioglycollate broth. After three days, the mice were sacrificed and then each mouse was injected with 4 mL RPMI 1640 into the peritoneal cavity. The peritoneal lavage fluid was collected and centrifuged at 300*g* for 5 min. The supernatant was removed and the cells were re-suspended in RPMI 1640 medium supplemented with 10% fetal bovine serum and maintained at 37 °C with 5% CO~2~. After 2 h, non-adherent cells were discarded. The remaining adherent cells were cultured overnight until they were used for the experiments.

2.7. Trans Epithelial Electric Resistance {#s0045}
-----------------------------------------

The Caco-2 cells were seeded in Transwell cell culture chambers (6.5-mm diameter inserts, 3.0 μm pore size) (Corning Costar, Cambridge, MA) and cultured for 11 days to form a cell monolayer. Then, RAW246.7 macrophages were seeded in the bottom of the well. After three days, the RAW246.7 macrophages were pre-treated with SB (5 mM) for 1 h and then stimulated with lipopolysaccharide (LPS) (1 μg/mL) for 24 h, as shown in [Fig. 5](#f0025){ref-type="fig"}A. The complete medium was replaced with serum free medium and incubated for 20 min, and then the TEER value was measured using a resistor:$$\text{TEER} = \frac{R - {RB}}{\mspace{14mu}\text{Surface\ Area}}\left( {\Omega/{cm}2} \right)$$Where R is the resistance of the cell monolayer along with the filter membrane, RB is the resistance of the filter membrane (black), and Surface Area = (0.65 cm ÷ 2)^2^ × 3.14 = 0.332 cm^2^.

2.8. Cell Co-Culture {#s0050}
--------------------

The RAW246.7 macrophages and Caco-2 cells were seeded in 6-well plates and cultured for 48 h. Then, the RAW246.7 macrophages were stimulated with LPS for 12 h. The medium supernatant was collected and centrifuged at 12,000 *g* for 10 min to remove cell debris. The collected medium supernatant was used to stimulate the Caco-2 cells for 12 h, as shown in [Fig. 5](#f0025){ref-type="fig"}C. The Caco-2 cells were collected to measure the expression of the tight junction encoding genes claudin-1 (*Cldn1*), occludin (*Ocln*), and *Zo1* using qRT-PCR.

2.9. RNA Extraction, Complementary DNA (cDNA) Preparation, and Real-time Reverse Transcription-Polymerase Chain Reaction (RT-PCR) {#s0055}
---------------------------------------------------------------------------------------------------------------------------------

Total RNA was extracted from the colon tissue, RAW246.7 macrophages, Caco-2 cells, and primary peritoneal macrophages using TRIzol (Invitrogen, Carlsbad, CA), and cDNA was generated using a commercial RT-PCR kit (TaKaRa Shuzo Co., Ltd., Kyoto, Japan). Then, real-time PCR was conducted using the SYBR Green QuantiTect RT-PCR kit (Roche, South San Francisco, CA), and each of the samples was analyzed in triplicate. The sequences of the primers used in this investigation are shown in [Table 1](#t0005){ref-type="table"}.

2.10. Western Blotting {#s0060}
----------------------

RAW246.7 cells and primary peritoneal macrophages were treated with SB (5 mM) for 1 h, and treated with LPS (1 μg/mL) for 2 h. Then, the cells were lysed with a lysis buffer (Beyotime Inst. Biotech, Beijing, China). The protein concentrations in the supernatants were quantified using a bicinchoninic acid protein assay kit (Beyotime Inst. Biotech), and 30 μg of protein was resolved by 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to immunoblot polyvinylidene difluoride membranes (Millipore, Billerica, MA). The membranes were blocked with 5% non-fat milk in Tris-buffered saline with 0.1% Tween (TBS-T) for 1 h, washed four times in TBS-T, followed by overnight incubation at 4 °C with primary antibodies against p-p38 (1:2000), p-38 (1:2000), p-JNK1/2 (1:2000), JNK1/2 (1:2000), p-ERK1/2 (1:2000), ERK1/2 (1:2000), p-AKT (1:2000), AKT (1:2000), p-NF-κB p65 (1:2000), NF-κB p65 (Cell Signaling Technology, Danvers, MA), and β-actin (1:2000) (Santa Cruz Technologies, Dallas, TX). Then, the membranes were again washed four times with TBS-T (15 min each time) and incubated with a horseradish peroxidase-labeled secondary goat anti-rabbit (1:2000; Santa Cruz Technologies) or rabbit anti-goat (1:2000; Santa Cruz Technologies) antibody for 1 h at room temperature. Next, the blots were washed again four times with TBS-T (15 min each time). Membranes were visualized using enhanced chemiluminescence (ECL kit; Applygen Inst. Biotech, Beijing, China).

2.11. Statistics {#s0065}
----------------

Results are expressed as the means ± SE. Data were analyzed using the statistical software package SPSS 12.0 (SPSS Inc., Chicago, IL). Groups were compared by one-way analysis of variance (ANOVA) followed by the least significant difference test. \**P* \< 0.05 was considered significant, and \*\**P* \< 0.01 was considered markedly significant.

3. Results {#s0070}
==========

3.1. SB Ameliorates Survival, Weight Loss, Colon Length, and Clinical Scores in a TNBS-Induced Mouse IBD Model {#s0075}
--------------------------------------------------------------------------------------------------------------

Initially, to define whether SB has a protective role in colitis *in vivo*, a series of indices were measured in TNBS-induced mice. First, we tested the survival of TNBS-induced *WT* and *GPR109a*^*−/−*^ mice and found no significant difference. Pre-treatment with SB for 2 months observably improved the *WT* mouse survival rate; however, the effect was not observed in *GPR109a*^*−/−*^ mice ([Fig. 1](#f0005){ref-type="fig"}A). Next, we measured the weight loss (initial weight − real time weight) and found that TNBS decreased the weight of *WT* and *GPR109a*^*−/−*^mice, whereas SB increased the body weight of *WT* mice but had no effect on *GPR109a*^*−/−*^ mice ([Fig. 1](#f0005){ref-type="fig"}B). TNBS decreased the colon length in *WT* and *GPR109a*^*−/−*^ mice, whereas pre-treatment with SB increased the colon length in *WT* mice but not in *GPR109a*^*−/−*^ mice ([Fig. 1](#f0005){ref-type="fig"}C). Lastly, we found that TNBS significantly increased the disease activity index in *WT* and *GPR109a*^*−/−*^ mice, and SB decreased the disease activity index in *WT* mice ([Fig. 1](#f0005){ref-type="fig"}D). Together, these results indicated that SB plays a GPR109A-dependent protective role in TNBS-induced colitis.Fig. 1SB ameliorates survival, weight loss, colon length, and disease activity index in the TNBS-induced mouse IBD model. *WT* and *GPR109a*^*−/−*^ mice were pre-treated with SB for 6 weeks and then treated with TNBS for 6 days. (A) Survival of TNBS- and SB-treated *WT* and *GPR109a*^*−/−*^mice (n = 14). (B) Weight loss (the previous day\'s body weight -- the day\'s body weight) in TNBS- and SB-treated *WT* and *GPR109a*^*−/−*^mice (n = 8--12). (C) Colon length in TNBS- and SB-treated *WT* and *GPR109a*^*−/−*^ mice (n = 8--12). (D) Disease activity index of TNBS- and SB-treated *WT* and *GPR109a*^*−/−*^mice (n = 8--12).Fig. 1

3.2. SB Suppresses Inflammation in TNBS-Induced Mice {#s0080}
----------------------------------------------------

The qRT-PCR results showed that TNBS significantly increased the expression of TNF-α and IL-1β in colon tissue homogenates of *WT* and *GPR109a*^*−/−*^ mice; however, pre-treatment with SB strikingly decreased their expression in *WT* but not in *GPR109a*^*−/−*^ mice ([Fig. 2](#f0010){ref-type="fig"} A,B). Evaluation of the severity of colonic inflammation and ulceration by histopathological examination showed marked infiltration of inflammatory cells, loss of crypts, destruction of the mucosal layer, and edema in TNBS-induced *WT* and *GPR109a*^*−/−*^ mice. In contrast, the colons of *WT* mice pre-treated with SB showed only mild inflammation; however, SB had no effects on TNBS-induced *GPR109a*^*−/−*^mice ([Fig. 2](#f0010){ref-type="fig"}C). The protective effects of SB on TNBS-induced mice were also observed in total damage score ([Fig. 2](#f0010){ref-type="fig"}D). The results indicated that SB suppressed the inflammation in TNBS-induced mice in a GPR109A-dependent manner.Fig. 2SB suppresses the inflammation in TNBS-induced mice.(A-B) Expression of the pro-inflammatory cytokines TNF-α and IL-6 in colon tissue homogenate (n = 4). (C) H&E staining of colon tissue from TNBS- and SB-treated *WT* and *GPR109a*^*−/−*^mice^*−*^, magnification shown is 4 ×, and the scale bar represents 100 μm (n = 4). (D) Total damage score of TNBS- and SB-treated WT and *GPR109a*^*−/−*^ mice (n = 8--12).Fig. 2

3.3. SB Reduces the Permeability and Maintains Proper Tight Junctions and Mucin-2 in TNBS-Induced Mice {#s0085}
------------------------------------------------------------------------------------------------------

SB decreased the intestinal permeability in TNBS-induced *WT* mice; however, SB had no effects in TNBS-induced *GPR109a*^*−/−*^mice ([Fig. 3](#f0015){ref-type="fig"}A). qRT-PCR assessment of *Cldn1*, *Zo1*, and *Ocln* mRNA expression showed that their expression was reduced in TNBS-induced *WT* and *GPR109a*^*−/−*^ mice, whereas supplementation with SB precluded this effect in TNBS-induced *WT* but not *GPR109a*^*−/−*^ mice ([Fig. 3](#f0015){ref-type="fig"}C-E). Immunofluorescence-mediated examination of mucin-2 (MUC2) protein expression showed that MUC2 was reduced in both TNBS-induced *WT* and *GPR109a*^*−/−*^ mice. *WT* mice maintained proper MUC2 protein expression when supplemented with SB, but no improvement was observed in *GPR109a*^*−/−*^ mice ([Fig. 3](#f0015){ref-type="fig"}B). Together, these results indicated that SB reduced the permeability and maintained proper tight junctions and mucin-2 by activating GPR109A in TNBS-induced mice.Fig. 3SB reduces the permeability and maintains proper tight junctions and mucin-2 in TNBS-induced mice.All mice were pre-treated with SB for 6 weeks, and then treated with TNBS for 2 days. (A) Relative permeability of TNBS and SB treatment in *WT* and *GPR109a*^*−/−*^ mice. After treating with SB and TNBS, the mice were starved for 4 h and then gavaged with FITC-dextran (0.6 mg/g body weight at a concentration of 125 mg/mL). Serum from blood collected after 4 h was used to measure the permeability (n = 4). (B) Immunofluorescence staining of Muc2 in the colon; magnification shown is 10 ×, and the scale bar represents 300 μm (n = 4). (C-E) Expression of the tight junction encoding genes *Cldn1*, *Ocln*, and *Zo1* in the colon tissue homogenate of TNBS- and SB-treated *WT* and *GPR109a*^*−/−*^ mice (n = 4).Fig. 3

3.4. SB Suppresses Pro-Inflammatory Cytokine Expression in LPS-Induced Macrophages {#s0090}
----------------------------------------------------------------------------------

qRT-PCR assessment of *in vitro* pro-inflammatory cytokine expression showed that TNF-α and IL-6 expression increased in 6-h-LPS-induced RAW246.7 cells. However, pre-treatment with SB sharply decreased the expression of pro-inflammatory mediators ([Fig. 4](#f0020){ref-type="fig"}A, B). In comparison, ELISA measurement of the levels of the pro-inflammatory cytokines in the supernatant of 12-h-LPS-induced RAW246.7 cells showed that SB pretreatment markedly inhibited the release of TNF-α and IL-6 ([Fig. 4](#f0020){ref-type="fig"}C, D).Fig. 4SB suppresses pro-inflammatory cytokine expression in LPS-induced macrophages.(A-B) Expression of TNF-α and IL-6 in SB- and LPS-treated RAW246.7 cells. RAW246.7 macrophages were stimulated with LPS for 6 h after pre-treating with SB for 1 h, and then the cells were collected with TRIzol. Gene expression of TNF-α and IL-6 was detected by qRT-PCR (*n* = 3). (C-D) Protein levels of TNF-α and IL-6 in the medium supernatant of SB- and LPS-treated RAW246.7 macrophages. RAW246.7 macrophages were pre-treated with SB for 1 h, and then stimulated with LPS for 12 h. The medium supernatant was collected and used for measuring the protein levels of TNF-α and IL-6 by ELISA (n = 3).Fig. 4

3.5. SB Maintains a Proper Intestinal Epithelium Barrier by Inhibiting the Inflammatory Response of Macrophages {#s0095}
---------------------------------------------------------------------------------------------------------------

To investigate the protective role of SB on the intestinal epithelium barrier *in vitro*, we simulated the intestinal physiological environment by culturing Caco-2 and RAW 246.7 cells together in a Transwell® plate ([Fig. 5](#f0025){ref-type="fig"}A). The results showed that LPS significantly decreased the resistance of the monolayer, whereas pre-treating with SB observably inhibited this reducing effect ([Fig. 5](#f0025){ref-type="fig"}B). Next, we also performed a co-culture experiment to confirm whether the protective effects of SB on the intestinal epithelium barrier occurred by inhibiting the inflammatory response of macrophages. The results showed that the medium supernatant of LPS-stimulated but not SB plus LPS-treated RAW246.7 macrophages significantly decreased the expression of *Cldn1*, *Zo1*, and *Ocln* ([Fig. 5](#f0025){ref-type="fig"} C-F). Together, the results indicated that SB maintained the proper epithelium barrier by inhibiting the secretion of pro-inflammatory mediators from macrophages.Fig. 5SB maintains a proper intestinal epithelium barrier by inhibiting the inflammatory response of macrophages.(A) Schematic diagram of the testing process of TEER. (B) TEER of various treatments of the Caco-2 monolayer (n = 3). (C) Schematic diagram of Caco-2 cell and RAW246.7 macrophage co-culture. (D-E) Expression of the tight junction genes *Cldn1*, *Ocln*, and *Zo1* of Caco-2 cells (n = 3).Fig. 5

3.6. SB Suppresses LPS-Induced Phosphorylation of the AKT and NF-κB p65 Signaling Pathways in Macrophages {#s0100}
---------------------------------------------------------------------------------------------------------

LPS sharply improved the phosphorylation of p-38, JNK1/2, ERK1/2, AKT, and NF-κB p65 signaling pathways in RAW246.7 cells ([Fig. 6](#f0030){ref-type="fig"}A, E), whereas SB pre-treatment significantly inhibited the phosphorylation of AKT and NF-κB p65(Fig. F,G), but not p-38, JNK1/2, and ERK1/2 in LPS-induced RAW246.7 macrophages ([Fig. 6](#f0030){ref-type="fig"}B-D). SB also clearly inhibited the phosphorylation of AKT and NF-κB p65 in LPS-induced *WT* mouse primary peritoneal macrophages ([Fig. 6](#f0030){ref-type="fig"}H-J), but failed to inhibit this phenomenon in LPS-induced *GPR109a*^*−/−*^ mouse primary peritoneal macrophages ([Fig. 6](#f0030){ref-type="fig"}K-M).Fig. 6SB suppresses LPS-induced phosphorylation of the AKT and NF-κB p65 signaling pathways in macrophages.(A-G) Western blot analysis of the phosphorylation of the p38, ERK p-38, JNK1/2, ERK1/2, AKT, and NF-κB p65 signaling pathways in LPS-induced RAW246.7 macrophages (n = 3). (H-J) Western blot analysis of the phosphorylation of the AKT and NF-κB p65 signaling pathways in LPS-induced *WT* mouse primary peritoneal macrophages (n = 3). (K-M) Western blot analysis of the phosphorylation of the AKT and NF-κB p65 signaling pathways in LPS-induced *GPR109a*^*−/−*^mouse primary peritoneal macrophages (n = 3).Fig. 6

4. Discussion {#s0105}
=============

A growing body of evidence suggests that the activation of GPR109A suppresses the inflammatory effects in various diseases ([@bb0170]; [@bb0200]; [@bb0250]; [@bb0255]). Additionally, previous studies showed that the activation of GPR109a inhibits the inflammation seen in IBD ([@bb0175]; [@bb0195]). However, these reports all focused on the anti-inflammatory effects of GPR109a and ignored the potential protective effects of GPR109A on the impaired intestinal epithelium barrier. Butyrate is produced by the intestinal microbial fermentation of dietary carbohydrates, fiber, proteins, and peptides ([@bb0075]; [@bb0115]). SB has been reported to decrease post-weaning diarrhea by modulating intestinal permeability in weaned piglets ([@bb0085]), promoting the recovering of intestinal wound healing through its positive effect on the tight junctions ([@bb0125]) and butyrate-releasing derivatives maintain proper *Zo1* and *Ocln* expression in the colons of patients with DSS-induced colitis ([@bb0190]). However, the effect of SB on impaired intestinal epithelium barriers is not clear. In the present study, we examined the anti-inflammatory property of SB; confirmed its potential protective roles on the impaired intestinal epithelium barrier in a TNBS-induced IBD mouse model; and explored its mechanism in RAW246.7 macrophages, Caco-2 cells, and primary peritoneal macrophages *in vitro*.

Depressed survival rate, body weight, and colon length along with elevated clinical score comprise the essential characteristics of IBD ([@bb0090]; [@bb0185]; [@bb0210]). In the present study, we found that SB improved the survival rate, body weight, and colon length and decreased the clinical score in TNBS-induced *WT* mice, but had no effects on *GPR109a*^*−/−*^mice. We also found that supplementation with SB markedly inhibited the inflammatory response in TNBS-induced mice and LPS-induced macrophages. The results are consistent with previous reports that activation of the GPR109A receptor provides a protective effect on IBD ([@bb0135]; [@bb0195]).Dietary fiber exhibits multiple beneficial effects toward the maintenance of intestinal homeostasis, which are believed to be due to the fermentation of fibers by intestinal microbiota, resulting in the production of short-chain fatty acids such as acetate, propionate, and butyrate ([@bb0100]). Among the short-chain fatty acids, butyrate has attracted more attention, being shown to function as an energy source for coloncytes, to exhibit anti-inflammatory as well as immune modulatory effects, and to protect against intestinal cancer in a GPR109A-dependent manner ([@bb0100]; [@bb0115]; [@bb0150]). Therefore, our results are consistent with those of previous studies wherein supplementation with fiber improves DSS- or TNBS-induced mouse colitis ([@bb0135]; [@bb0155]), quite possibly in a GPR109A-dependent manner.

The intestinal epithelium, among the most important interfaces between the body and the environment, not only plays a part in nutrient absorption but also acts as a barrier against the vast amount of commensal intestinal microorganisms and pathogenic microbes ([@bb0005]; [@bb0160]). Therefore, the integrity of the epithelial monolayer is critical for the health of the gut, and epithelial dysfunction is a hallmark of intestinal disorders such as IBDs ([@bb0035]; [@bb0245]). In the TNBS-induced murine colitis model, ethanol is essential for providing access to intestinal epithelial cells, impairing barrier function, and allowing TNBS to penetrate the bowel wall. TNBS constitutes a covalently reactive compound that attaches to autologous proteins and stimulates a delayed-type hypersensitivity response to hapten-modified self antigens, a reaction that involves and is regulated by complex interactions among various functional subsets of CD4^+^ T cells ([@bb0045]; [@bb0140]), subsequently leading to the inflammatory response of innate immune cells and further damage of the intestinal epithelium barrier. In the present study, we found that SB reduced the permeability of the intestine and maintained proper tight junctions and MUC2 in the colon of TNBS-induced *WT* mice. To further confirm these results, we examined the effects of SB on the epithelium barrier *in vitro* and found that SB sharply reduced the effects of LPS-induced RAW246.7 macrophages on the resistance of the Caco-2 cell monolayer, as well as maintained proper tight junctions. Together, these results indicated that SB maintained a proper intestinal epithelium barrier by activating GPR109A.

A previous study indicated that GPR109a mediates the anti-inflammatory effect by inhibiting the phosphorylation of the NF-κB p65 signaling pathway ([@bb0060]; [@bb0260]). In the present study, to investigate the definite mechanism of SB on the inflammatory response, we examined the effects of SB on the classical inflammation pathways AKT, NF-κB, and MAPK and found that supplementation with SB markedly decreased the phosphorylation of AKT and NF-κB p65 in LPS-induced RAW246.7 cells and *WT* mouse primary peritoneal macrophages, but failed to suppress this phenomenon in *GPR109a*^*−/−*^ mouse primary peritoneal macrophages. Previous studies indicated that supplementation with SB improved the phosphorylation of the AKT signaling pathway in high-fat diet--induced insulin resistance ([@bb0070]; [@bb0265]), elevated the phosphorylation of the AKT signaling pathway in the adipose tissue of obese mice ([@bb0080]), and inhibited platelet-derived growth factor-induced proliferation and migration in pulmonary artery smooth muscle cells through AKT inhibition ([@bb0020]). Therefore, the effects of SB on the AKT signaling pathway are not fixed; instead, they depend on the function of the AKT signaling pathway in different situations. Our results indicated that SB inhibited the phosphorylation of the AKT and NF-κB p65 signaling pathway in macrophages in a GPR109A-dependent manner.

[Fig. 7](#f0035){ref-type="fig"} summarizes the underlying mechanism of SB on inhibiting inflammation and maintaining epithelium barrier integrity in the TNBS-induced colitis model. Our findings not only explained the protective effect of SB on colon health, but also provided evidence that GPR109A likely constitutes a valid therapeutic target in IBD. Inhibition of macrophages by activating GPR109A thus may represent a novel approach to treat IBD.Fig. 7Mechanism of sodium butyrate on inhibiting inflammation and maintaining epithelium barrier integrity in the TNBS-induced colitis model.Fig. 7
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